You are here

  • Home
  • Archive
  • Volume 6, Issue 3
  • Interferon β-1a prevented the development of clinically definite multiple sclerosis after a first demyelinating event

Article Text

Article menu
Download PDFPDF
Therapeutics
Interferon β-1a prevented the development of clinically definite multiple sclerosis after a first demyelinating event

https://doi.org/10.1136/ebm.6.3.78

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    (2000) N Engl J Med 343, 898. Jacobs LD, Beck RW, Simon JH, et al,. and the CHAMPS Study Group. . Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. . . Sep 28;. :. –904..
    OpenUrlCrossRefPubMedWeb of Science

    
 
 QUESTION: In patients with a first confirmed demyelinating event, does interferon β-1a reduce the incidence of clinically definite multiple sclerosis (MS)?

    Design

    Randomised {allocation concealed*}†, blinded (patients, clinicians, and outcome assessors),* placebo controlled trial with 3 years of follow up (Controlled High Risk Subject Avonex Multiple Sclerosis Prevention Study [CHAMPS]). An interim analysis was planned.

    Setting

    50 clinical centres in North America.

    Patients

    383 patients (mean age 33 y, 75% women, 86% white) who had a first acute clinical demyelinating event confirmed by magnetic resonance imaging (MRI). Inclusion criteria were age 18–50 years; involvement of optic nerve, spinal cord, brain stem, or cerebellum; ≥2 clinically silent brain lesions ≥3 mm in diameter; and symptom onset <14 days from corticosteroid treatment and <27 days from …

    View Full Text